Results 31 to 40 of about 7,047 (156)
, 2020 We have recently shown that XPO1 mutations are drivers of lymphomagenesis and occur across B-cell lymphomas, specifically in chronic lymphocytic leukemia (CLL), classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma.
Lee, Stanley +3 more
core +1 more source
, 2021 Mutations in the nuclear exporter XPO1 and the spliceosomal protein SF3B1 are bona fide cancer drivers and occur across a spectrum of hematologic cancers, specifically in chronic lymphocytic leukemia (CLL), myelodysplastic syndromes (MDS) and acute ...
Chaudhry, Sana +3 more
core +1 more source
Give me a SINE: how Selective Inhibitors of Nuclear Export modulate autophagy and aging
Molecular & Cellular Oncology, 2018 Autophagy is a cellular recycling process leading to lysosomal degradation of damaged macromolecules, which can protect cells against aging. The transcription factor EB (TFEB), a major transcriptional regulator of genes involved in autophagy and ...
A.V. Kumar +5 more
doaj +1 more source
PLoS ONE, 2015 The DEAD-box RNA helicase Ded1, which is essential in yeast and known as DDX3 in humans, shuttles between the nucleus and cytoplasm and takes part in several basic processes including RNA processing and translation.
Glenn Hauk, Gregory D Bowman
doaj +1 more source
Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones
Pharmaceuticals, 2021 The nuclear export receptor exportin-1 (XPO1, CRM1) mediates the nuclear export of proteins that contain a leucine-rich nuclear export signal (NES) towards the cytoplasm.
Marta Gargantilla +6 more
doaj +1 more source
Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma
Journal of Hematology & Oncology, 2019 Double-hit lymphoma (DHL) is among the most aggressive and chemoresistant lymphoma subtypes. DHLs carry genomic abnormalities in MYC, BCL2, and/or BCL6 oncogenes. Due to the simultaneous overexpression of these driver oncogenes, DHLs are highly resistant
Yuanhui Liu +4 more
doaj +1 more source
Translational Oncology, 2021 Across many cancer types in adults, upregulation of the nuclear-to-cytoplasmic transport protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an FDA-approved XPO1 inhibitor.
Basia Galinski +9 more
doaj +1 more source
, 2023 Exportin 1 (XPO1) is overexpressed in several solid tumors, and is associated with poor prognosis. Here, we aimed to evaluate the implication of XPO1 expression in solid tumors through a meta-analysis.
Gang Chen (107840) +9 more
core +1 more source
Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors
Biomolecules, 2023 Exportin-1 (XPO1) is a key player in the nuclear export pathway and is overexpressed in almost all cancers. This is especially relevant for non-Hodgkin lymphoma (NHL), where high XPO1 expression is associated with poor prognosis due to its oncogenic role
Kyla L. Trkulja +3 more
doaj +1 more source
Advanced Materials, EarlyView.Cancer‐associated NPC remodeling creates a high‐flux, low‐stringency nuclear state that supports malignant adaptation but increases mechanical fragility. Targeting the FG‐barrier or NPC scaffold may drive mechanostat failure, envelope rupture, DNA damage, and loss of nuclear integrity.
Sílvio Terra Stefanello +5 more
wiley +1 more source